.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Merck
Daiichi Sankyo
McKesson
Queensland Health
UBS
Express Scripts
Novartis
McKinsey
Baxter

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,194,247

« Back to Dashboard

Claims for Patent: 5,194,247

Title: Synergistic skin depigmentation composition
Abstract:There is disclosed a synergistic composition for skin depigmentation with reduced irritation which does not contain a corticosteroid comprising 4-hydroxyanisole and a retinoid, such as all-trans retinoic acid, 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone or (N-acetyl-4-aminophenyl) retinoate, in a pharmaceutically acceptable topical vehicle.
Inventor(s): Nair; Xina (E. Amherst, NY), Tramposch; Kenneth M. (Williamsville, NY)
Assignee:
Application Number:07/554,904
Patent Claims: 1. A synergistic composition for skin depigmentation which does not contain a corticosteroid and which consists essentially of from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight at least one retinoid selected from the group consisting of all-trans retinoic acid, (N-acetyl-4-amino-phenyl) retinoate and 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone in a pharmaceutically acceptable topical vehicle.

2. A composition as defined in claim 1 wherein said retinoid is all-trans retinoic acid.

3. A composition as defined in claim 2 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01 to 0.1% by weight of all-trans retinoic acid.

4. A composition as defined in claim 1 wherein said retinoid is (N-acetyl-4-aminophenyl) retinoate.

5. A composition as defined in claim 4 containing from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight of (N-acetyl-4-aminophenyl) retinoate.

6. A composition as defined in claim 5 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01 to 0.1% by weight of (N-acetyl-4-aminophenyl) retinoate.

7. A composition as defined in claim 1 wherein said retinoid is 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

8. A composition as defined in claim 7 containing from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight of 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

9. A composition as defined in claim 8 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01 to 0.1% by weight of 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

10. A method depigmenting skin which comprises topically applying to the skin a synergistic composition which does not contain a corticosteroid consisting essentially of from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight at least one retinoid selected from the group consisting of all-trans retinoic acid, (N-acetyl-4-aminophenyl) retinoate and 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone in a pharmaceutically acceptable topical vehicle.

11. A method as defined in claim 10 wherein said retinoid is all-trans retinoic acid.

12. A method as defined in claim 1 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01% to 0.1% by weight of all-trans retinoic acid.

13. A method as defined in claim 10 wherein said retinoid is (N-acetyl-4-aminophenyl) retinoate.

14. A method as defined in claim 13 wherein said composition contains from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight of (N-acetyl-4-aminophenyl) retinoate.

15. A method as defined in claim 14 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01% to 0.1% by weight of (N-acetyl-4-aminophenyl) retinoate.

16. A method as defined in claim 10 wherein said retinoid is 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

17. A method as defined in claim 16 wherein said composition contains from 0.1% to 5% by weight of 4-hydroxyanisole and from 0.001% to 1% by weight of 11-cis-13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

18. A method as defined in claim 17 containing from 1 to 2% by weight of 4-hydroxyanisole and from 0.01% to 0.1% by weight of 11-cis,13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Farmers Insurance
Argus Health
Healthtrust
Cantor Fitzgerald
Covington
Daiichi Sankyo
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot